probenecid has been researched along with Hyperlipidemias in 8 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Hyperlipidemias: Conditions with excess LIPIDS in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "23 patients with hyperlipidemia and hyperuricemia received acetamidoethyl-(4-chlorophenyl)-(trifluoromethylphenoxy)-acetate (halofenate), a clofibrate derivative, and probenecid or probenecid and placebo over 36 weeks following a placebo period of 6 weeks." | 6.64 | [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate]. ( Keller, C; Wolfram, G; Zöllner, N, 1976) |
| "Halofenate is a new antilipemic drug which is an ester of carboxylic acid." | 2.64 | The metabolic spectrum of halofenate. ( Ryan, JR, 1975) |
| "23 patients with hyperlipidemia and hyperuricemia received acetamidoethyl-(4-chlorophenyl)-(trifluoromethylphenoxy)-acetate (halofenate), a clofibrate derivative, and probenecid or probenecid and placebo over 36 weeks following a placebo period of 6 weeks." | 2.64 | [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate]. ( Keller, C; Wolfram, G; Zöllner, N, 1976) |
| "Gout is increasingly recognized as the most common form of inflammatory arthritis worldwide; however, no Canadian data on the disease burden of gout are available." | 1.46 | The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012. ( Aviña-Zubieta, JA; Choi, HK; De Vera, MA; McCormick, N; Rai, SK; Sayre, EC; Shojania, K, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (87.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rai, SK | 1 |
| Aviña-Zubieta, JA | 1 |
| McCormick, N | 1 |
| De Vera, MA | 1 |
| Shojania, K | 1 |
| Sayre, EC | 1 |
| Choi, HK | 1 |
| Ryan, JR | 1 |
| Bassett, DR | 1 |
| Mikkelsen, WM | 1 |
| Buckingham, RB | 1 |
| Block, WD | 1 |
| Sidiq, M | 1 |
| Shakibai, A | 1 |
| DiGaetano, R | 1 |
| Liou, LL | 1 |
| Gibson, T | 2 |
| Kilbourn, K | 1 |
| Horner, I | 1 |
| Simmonds, HA | 1 |
| Keller, C | 1 |
| Wolfram, G | 1 |
| Zöllner, N | 1 |
| Grahame, R | 1 |
| Bluestone, R | 1 |
| Lewis, B | 1 |
| Mervart, I | 1 |
| Holländer, E | 1 |
| Schwarczmann, P | 1 |
3 trials available for probenecid and Hyperlipidemias
| Article | Year |
|---|---|
The metabolic spectrum of halofenate.
Topics: Blood Glucose; Cholesterol; Clinical Trials as Topic; Clofibrate; Creatine Kinase; Glycolates; Halof | 1975 |
Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
Topics: Adult; Aged; Body Weight; Cholesterol; Clinical Trials as Topic; Female; Glycolates; Halofenate; Hum | 1977 |
[Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
Topics: Cholesterol; Clinical Trials as Topic; Female; Glycolates; Halofenate; Humans; Hyperlipidemias; Male | 1976 |
5 other studies available for probenecid and Hyperlipidemias
| Article | Year |
|---|---|
The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012.
Topics: Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; British Columbia; Colchicine; Comorbidit | 2017 |
Mechanism and treatment of hypertriglyceridaemia in gout.
Topics: Alcohol Drinking; Allopurinol; Cholesterol; Gout; Humans; Hyperlipidemias; Male; Middle Aged; Obesit | 1979 |
Gout and hyperlipidaemia.
Topics: Adult; Aged; Alcohol Drinking; Allopurinol; Aspartate Aminotransferases; Body Height; Body Weight; C | 1974 |
Hyperlipoproteinaemia in gout.
Topics: Adult; Aged; Allopurinol; Blood Protein Disorders; Blood Protein Electrophoresis; Cholesterol; Gout; | 1971 |
[Gout in advanced age].
Topics: Age Factors; Aged; Allopurinol; Bone and Bones; Cardiovascular Diseases; Colchicine; Female; Gout; H | 1968 |